Trial Profile
Phase II Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Panobinostat (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 01 Jun 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 06 Nov 2012 Planned end date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 16 Mar 2011 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.